Anxiety disorders are clinical conditions with decades of established care behind them. What cannabidiol has is a handful of one-afternoon public-speaking experiments and a marketing budget orders of magnitude larger.
The short answer
No — not on this evidence.
The strongest result: in a 2017 trial in Frontiers in Pharmacology, 12 healthy volunteers given 300 mg before a real public-speaking test scored lower on the Visual Analogue Mood Scale anxiety factor than 12 on placebo. The problem: 100 mg and 900 mg in that same trial did not, and a 2024 review of 11 randomised trials covering 673 people found the results too contradictory to pool.
Key takeaways
- The three most-cited human trials randomised 24, 60 and 37 people — 121 between them.
- Two of the three measured one dose against one stressful afternoon. Only one ran longer than a day.
- 300 mg is the dose that keeps appearing. A typical gummy is 25 mg — twelve of them.
- The only FDA-approved cannabidiol drug is Epidiolex, for seizures — at 10–20 mg/kg/day, roughly 700–1,400 mg daily for a 70 kg adult.
- The FDA has concluded CBD is excluded from the dietary supplement definition and may not be added to food.
What the trials actually measured
Three studies do most of the work in everything written on this subject. Each measured something specific — and narrower than the headlines sound.
| Study | Who | What they took | What the paper reported |
|---|---|---|---|
| Bergamaschi 2011 Neuropsychopharmacology | 24 with social anxiety disorder (12 CBD / 12 placebo) + 12 untreated controls | 600 mg, single dose, 90 minutes before a simulated public-speaking test | Lower scores than placebo on the Visual Analogue Mood Scale and the Negative Self-Statement scale (SSPS-N) |
| Zuardi 2017 Frontiers in Pharmacology | 60 healthy volunteers aged 18–35, 12 per arm | Placebo, clonazepam 1 mg, or CBD at 100, 300 or 900 mg before a real speech | Only the 300 mg arm scored below placebo on the VAMS anxiety factor post-speech. 100 mg and 900 mg did not. |
| Masataka 2019 Frontiers in Psychology | 37 Japanese 18–19-year-olds with social anxiety disorder (17 CBD / 20 placebo) | 300 mg daily for four weeks | Scores fell versus placebo on both the Fear of Negative Evaluation questionnaire and the Liebowitz Social Anxiety Scale |
What those numbers are not
- Not a condition tracked over time. The endpoints are mood-scale scores during a speech, not how anyone’s month went.
- Not large. Twelve people per arm is a pilot. Results that small shift on one outlier.
- Not consistent. The 2024 review in Life found the disorders, doses and designs across its 11 trials too different to combine.
- Not what’s on the shelf. Every trial used a measured oral dose of purified cannabidiol. A gummy is a different product at a different dose.
The dose in the research is not the dose on the label
300 mg keeps showing up because that’s where two separate groups saw a signal. Almost nothing on a wellness shelf comes close: a 25 mg gummy is a twelfth of it, and a 1,000 mg tincture bottle holds three.
The curve is not a ramp either. In the 2017 trial, 900 mg landed back at placebo — tripling the dose erased the difference. “Take more” has nothing behind it here.
No regulator has set a dose, so there isn’t one. Our beginner dosage guide covers why start-low-go-slow is about tolerability rather than results.
What the FDA has actually approved
One cannabidiol drug. Epidiolex is a purified prescription formulation for seizures associated with Lennox-Gastaut or Dravet syndrome, in patients one year and older. Not anxiety.
The approval CBD marketing leans on is for a different condition, at doses nobody sells. Epidiolex starts at 5 mg/kg/day, maintains at 10 and tops out at 20 — roughly 700 to 1,400 mg a day for a 70 kg adult, prescribed with liver-enzyme monitoring because the FDA identified a potential for liver injury while reviewing it.
CBD also falls outside the dietary supplement definition and may not be added to food, so everything on the shelf is unapproved — nobody has assessed its dose, interactions or safety. A current third-party certificate of analysis is the floor, not a feature. See our methodology.
Who should not try it
- Anyone taking prescription medication. First for a reason. CBD competes for the liver enzymes that clear a long list of drugs, and the FDA warns that combining it with alcohol or anything that slows brain activity raises the sedation risk. Ask a pharmacist first.
- Anyone whose anxiety has lasted weeks, or is shaping their days. That is a clinician, not a supplement — and the FDA specifically warns that unapproved products influence people away from approved therapies.
- Pregnant or nursing. The FDA advises against it. Animal studies showed male reproductive toxicity, including in offspring.
- Anyone with liver disease, or on drugs that stress it. The Epidiolex review found liver-injury signs sometimes visible only in blood work.
- Anyone subject to workplace drug testing. Full-spectrum products carry trace THC (0.3% or less) that can occasionally register.
So — is it worth trying?
Before one specific stressful event it’s a cheap experiment that fails fast: one product, one dose, one occasion, an honest verdict. As a standing answer to something shaping your life, it’s a poor bet in a safe costume.
Do the free things first. Sleep, caffeine timing and daylight cost nothing and are the likeliest variables — better sleep naturally and caffeine and sleep are the unglamorous starting points. After that, what a label does and doesn’t tell you at least tells you what you took.
Questions people ask
Will CBD show up on a drug test?
Pure CBD shouldn’t. Full-spectrum products contain trace THC that can occasionally trigger a positive, and the screening method matters more than the label. If you’re tested at work, choose isolate or skip it.
Can I take it alongside my prescription?
That’s a question for your pharmacist, not a website. CBD shares metabolic pathways with many medications, and the FDA flags added sedation when it’s combined with alcohol or anything that slows brain activity.
What about panic attacks specifically?
No trial above measured them. The studies used public-speaking stress and social anxiety scales in people aged 18 to 35. Panic disorder is a separate condition with its own evidence base.
Will it make me feel high?
No. The intoxicating compound in cannabis is THC; CBD is a different molecule and is non-intoxicating. Hemp-derived products are capped at 0.3% THC — what’s actually in the bottle depends on current lab results.
Sources
- Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients — Neuropsychopharmacology, 2011;36:1219–1226.
- Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life — Frontiers in Pharmacology, 2017;8:259.
- Anxiolytic Effects of Repeated Cannabidiol Treatment in Teenagers With Social Anxiety Disorders — Frontiers in Psychology, 2019;10:2466.
- The Impact of Cannabidiol Treatment on Anxiety Disorders: A Systematic Review of Randomized Controlled Clinical Trials — Life, 2024;14(11):1373.
- FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD) — U.S. Food and Drug Administration, current as of July 2024.
- EPIDIOLEX (cannabidiol) oral solution — prescribing information — U.S. Food and Drug Administration, 2018.
- What You Need to Know About Products Containing Cannabis or Cannabis-derived Compounds, Including CBD — U.S. Food and Drug Administration, 2020.
How we make money. Some links on this page are affiliate links. If you buy through one, we may earn a commission at no extra cost to you. It does not change what we write — see our affiliate disclosure.
These statements have not been evaluated by the Food and Drug Administration. CBD products are not intended to diagnose, treat, cure or prevent any disease. Serene Leaf does not physically test products; our assessments are based on published research, third-party lab reports and publicly available product information.
This article is information, not medical advice. Talk to a qualified healthcare provider before starting any supplement — especially if you are pregnant, nursing, taking medication or managing a diagnosed condition. 21+ only.